James Crowe Jr. Archives
Nov. 17, 2022—Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Nov. 3, 2022—The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.
Aug. 24, 2022—A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.
Jun. 8, 2022—Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM).
May. 5, 2022—The 2022 Vanderbilt University School of Medicine Academic Enterprise Awards for Excellence in Teaching, Extraordinary Performance of Clinical Service, and Outstanding Contributions to Research were presented April 29 during the annual spring faculty meeting.
Apr. 21, 2022—Physician-scientists from Vanderbilt University Medical Center were well represented at the recent annual meeting of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP) and the American Physician-Scientist Association.
Mar. 31, 2022—Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19.
Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
Dec. 2, 2021— by Bill Snyder The global biopharmaceutical company AstraZeneca announced more good news about its long-acting combination of two monoclonal antibodies against COVID-19 that were discovered at Vanderbilt University Medical Center. In a prevention trial, one prophylactic, intramuscular injection of the antibody combination, called AZD7442, reduced the risk of symptoms occurring after exposure to the...